GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
- Written by PR Newswire
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in Perth, Australia in a phase Ib/II trial of GFH018 in...
